Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tenax Therapeutics (TENX) Research & Development (2016 - 2026)

Tenax Therapeutics' Research & Development history spans 7 years, with the latest figure at $7.1 million for Q4 2017.

  • On a quarterly basis, Research & Development fell 70.29% to $7.1 million in Q4 2017 year-over-year; TTM through Dec 2017 was $3.5 million, a 83.22% decrease, with the full-year FY2025 number at $32.7 million, up 157.08% from a year prior.
  • Research & Development hit $7.1 million in Q4 2017 for Tenax Therapeutics, up from -$253973.0 in the prior quarter.
  • Over the last five years, Research & Development for TENX hit a ceiling of $23.7 million in Q4 2016 and a floor of -$3.4 million in Q2 2016.
  • Historically, Research & Development has averaged $2.8 million across 4 years, with a median of $844523.0 in 2013.
  • The widest YoY moves for Research & Development: up 266.23% in 2016, down 292.71% in 2016.
  • Tracing TENX's Research & Development over 4 years: stood at $844523.0 in 2013, then skyrocketed by 667.87% to $6.5 million in 2015, then soared by 266.23% to $23.7 million in 2016, then plummeted by 70.29% to $7.1 million in 2017.
  • Business Quant data shows Research & Development for TENX at $7.1 million in Q4 2017, -$253973.0 in Q3 2017, and -$1.2 million in Q2 2017.